AU2013258027B2 - 18F-labelled follate/antifolate analogues - Google Patents

18F-labelled follate/antifolate analogues Download PDF

Info

Publication number
AU2013258027B2
AU2013258027B2 AU2013258027A AU2013258027A AU2013258027B2 AU 2013258027 B2 AU2013258027 B2 AU 2013258027B2 AU 2013258027 A AU2013258027 A AU 2013258027A AU 2013258027 A AU2013258027 A AU 2013258027A AU 2013258027 B2 AU2013258027 B2 AU 2013258027B2
Authority
AU
Australia
Prior art keywords
folate
independently
acid
alkyl
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013258027A
Other languages
English (en)
Other versions
AU2013258027A1 (en
Inventor
Simon Mensah Ametamey
Thomas Betzel
Viola Groehn
Rudolf Moser
Cristina Magdalena Muller
Roger Schibli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck & Cie
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie filed Critical Merck & Cie
Publication of AU2013258027A1 publication Critical patent/AU2013258027A1/en
Application granted granted Critical
Publication of AU2013258027B2 publication Critical patent/AU2013258027B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013258027A 2012-05-08 2013-05-08 18F-labelled follate/antifolate analogues Active AU2013258027B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167126.7 2012-05-08
EP12167126 2012-05-08
PCT/EP2013/059584 WO2013167653A1 (en) 2012-05-08 2013-05-08 18f-labelled folate/antifolate analogues

Publications (2)

Publication Number Publication Date
AU2013258027A1 AU2013258027A1 (en) 2014-11-13
AU2013258027B2 true AU2013258027B2 (en) 2017-11-30

Family

ID=48407549

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013258027A Active AU2013258027B2 (en) 2012-05-08 2013-05-08 18F-labelled follate/antifolate analogues

Country Status (17)

Country Link
US (1) US10357576B2 (cg-RX-API-DMAC7.html)
EP (1) EP2864329B1 (cg-RX-API-DMAC7.html)
JP (1) JP6198814B2 (cg-RX-API-DMAC7.html)
KR (1) KR102116000B1 (cg-RX-API-DMAC7.html)
CN (1) CN104379585B (cg-RX-API-DMAC7.html)
AU (1) AU2013258027B2 (cg-RX-API-DMAC7.html)
CA (1) CA2870124C (cg-RX-API-DMAC7.html)
DK (1) DK2864329T3 (cg-RX-API-DMAC7.html)
EA (1) EA201401225A1 (cg-RX-API-DMAC7.html)
ES (1) ES2703627T3 (cg-RX-API-DMAC7.html)
IL (1) IL235476B (cg-RX-API-DMAC7.html)
PL (1) PL2864329T3 (cg-RX-API-DMAC7.html)
PT (1) PT2864329T (cg-RX-API-DMAC7.html)
SG (1) SG11201406481TA (cg-RX-API-DMAC7.html)
TR (1) TR201819802T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013167653A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201407266B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
AU2018237784B2 (en) * 2017-03-20 2022-04-21 Merck Patent Gmbh Isomerically pure 18F-labelled tetrahydrofolates
EP3671511B1 (en) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Communication system and method
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125617A2 (en) * 2007-04-11 2008-10-23 Merck Eprova Ag 18f-labelled folates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592302C (en) 2004-12-23 2013-10-29 Purdue Research Foundation Positron emission tomography imaging method
JP4503039B2 (ja) 2006-04-27 2010-07-14 三洋電機株式会社 回路装置
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20100143249A1 (en) 2007-04-11 2010-06-10 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
CN101646639A (zh) 2007-04-11 2010-02-10 默克阿泼洛发股份公司 18f-标记的叶酸
WO2008125615A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18 f-labelled folates
CA2736861C (en) 2008-10-10 2017-11-14 Roger Schibli 18f-labelled folates as pet radiotracers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125617A2 (en) * 2007-04-11 2008-10-23 Merck Eprova Ag 18f-labelled folates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERTS, E. C. ET AL., J. Med. Chem., 1971, Vol. 14 (2), pages 125-130 *
ROBERTS, E. C. ET AL., J. Med. Chem., 1972, Vol. 15 (12), pages 1310-1312 *

Also Published As

Publication number Publication date
WO2013167653A1 (en) 2013-11-14
ES2703627T3 (es) 2019-03-11
IL235476A0 (en) 2014-12-31
US20150125390A1 (en) 2015-05-07
CN104379585A (zh) 2015-02-25
AU2013258027A1 (en) 2014-11-13
KR20150010970A (ko) 2015-01-29
TR201819802T4 (tr) 2019-01-21
JP2015516405A (ja) 2015-06-11
CN104379585B (zh) 2018-07-06
PL2864329T3 (pl) 2019-03-29
ZA201407266B (en) 2016-09-28
CA2870124A1 (en) 2013-11-14
SG11201406481TA (en) 2014-11-27
CA2870124C (en) 2021-02-16
DK2864329T3 (en) 2019-01-21
EP2864329B1 (en) 2018-09-26
KR102116000B1 (ko) 2020-05-29
PT2864329T (pt) 2019-01-10
JP6198814B2 (ja) 2017-09-20
US10357576B2 (en) 2019-07-23
IL235476B (en) 2019-09-26
HK1202548A1 (en) 2015-10-02
EA201401225A1 (ru) 2015-04-30
EP2864329A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
US10357576B2 (en) 18F-labelled folate/antifolate analogues
AU2008237932C1 (en) 18 F-labelled folates
US9771368B2 (en) 18F-labelled folates
US10377756B2 (en) 18F-labelled folates
CA2736861A1 (en) 18f-labelled folates as pet radiotracers
HK1202548B (en) 18f-labelled folate/antifolate analogues
HK1138575A (en) 18f-labelled folates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)